MétaCan
Menu
Back to cohort
Record W4415341523 · doi:10.51594/imsrj.v5i8.2073

Pharmaceutical market analytics for therapeutic equity: Data-Driven models for expanding access to essential medicines

2025· article· W4415341523 on OpenAlexaff
Paul-Miki R. Ibekwe, Chinyere E. Ekanem, Joy O. Adesina, Chidinma I. Onyeibor

Bibliographic record

VenueInternational Medical Science Research Journal · 2025
Typearticle
Language
FieldEconomics, Econometrics and Finance
TopicPharmaceutical Economics and Policy
Canadian institutionsChild, Adolescent and Family Mental Health
Fundersnot available
KeywordsAnalyticsTransparency (behavior)Essential medicinesPredictive analyticsEquity (law)Big dataCorporate governancePharmaceutical industryPersonalized medicine

Abstract

fetched live from OpenAlex

Equitable access to essential medicines remains one of the most pressing global health challenges of the twenty-first century. Despite scientific and technological advances in drug development, millions in low- and middle-income countries (LMICs) still face barriers to affordable and timely treatment. This gap between innovation and accessibility—often driven by fragmented data systems, weak regulatory infrastructures, and market inefficiencies—underscores the need for pharmaceutical market analytics as a strategic tool for achieving therapeutic equity. This manuscript explores how data-driven models can transform medicine availability, affordability, and distribution through predictive analytics, real-time demand forecasting, and adaptive pricing algorithms. By leveraging artificial intelligence (AI) and real-world data, market analytics can identify underserved populations, optimize supply chains, and inform fair pricing mechanisms. Furthermore, the paper proposes a framework for ethical and equitable pharmaceutical market intelligence that integrates analytics, policy, and governance to ensure transparency and sustainability. Case examples from global access initiatives, such as insulin distribution programs and the WHO Global Price Reporting Mechanism, illustrate how analytics can close existing equity gaps. Ultimately, this paper argues that the future of pharmaceutical access depends not only on innovation in science but also on innovation in data systems—where evidence-based analytics empower stakeholders to design inclusive and resilient health markets. The findings highlight the critical intersection between data science, policy, and ethics in achieving universal access to essential medicines. Keywords: Pharmaceutical Analytics, Therapeutic Equity, Market Access.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.028
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.013
Threshold uncertainty score0.041

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0080.028
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0020.002
Science and technology studies0.0010.002
Scholarly communication0.0050.006
Open science0.0020.003
Research integrity0.0030.004
Insufficient payload (model declined to judge)0.0090.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.510
GPT teacher head0.606
Teacher spread0.096 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueInternational Medical Science Research JournalSame topicPharmaceutical Economics and PolicyFrench-language works237,207